A Phase I Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults
Latest Information Update: 16 Apr 2025
At a glance
- Drugs AZD 5148 (Primary) ; AZD 5148 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 21 Jan 2025 Planned primary completion date changed from 17 Feb 2025 to 7 Nov 2025.
- 11 Nov 2024 Planned End Date changed from 21 Nov 2025 to 7 Nov 2025.
- 11 Nov 2024 Planned primary completion date changed from 18 Feb 2025 to 17 Feb 2025.